Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

COVID-19 Resources »      Vaccine Update »      Visitor Policy »

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Smith, P. F., Robbins, G. K., Shafer, R. W., Wu, H. L., Yu, S., Hirsch, M. S., Merigan, T. C., Park, J. G., Forrest, A., Fischl, M. A., Morse, G. D. 2005; 49 (8): 3558-3561

Abstract

Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

View details for DOI 10.1128/AAC.49.8.3558-3561.2005

View details for Web of Science ID 000230950700074

View details for PubMedID 16048984

View details for PubMedCentralID PMC1196281